|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
173,970,000 |
Market
Cap: |
4.80(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$13.54 - $43.89 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile BridegeBio Pharma identifies and improves medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Co.'s pipeline are: Acoramidis/AG10/BBP-265, a small molecule transthyretin (TTR) stabilizer for the treatment of TTR amyloidosis; Infigratinib/BBP-831, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer for the treatment of congenital adrenal hyperplasia; and Encaleret, a small molecule antagonist of the calcium sensing receptor for the treatment of Autosomal Dominant Hypocalcemia Type 1.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
2,500 |
115,745 |
1,769,632 |
2,886,602 |
Total Sell Value |
$85,000 |
$4,770,514 |
$61,715,300 |
$73,415,196 |
Total People Sold |
1 |
3 |
6 |
6 |
Total Sell Transactions |
1 |
7 |
14 |
29 |
End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kumar Neil |
CEO and President |
|
2020-07-02 |
4 |
AS |
$30.22 |
$1,706,022 |
I/I |
(56,445) |
2,165,372 |
|
45% |
|
Kumar Neil |
CEO and President |
|
2020-07-01 |
4 |
AS |
$30.63 |
$2,705,335 |
I/I |
(87,025) |
2,221,817 |
|
35% |
|
Stephenson Brian C |
See Remarks |
|
2020-07-01 |
4 |
AS |
$30.64 |
$334,053 |
D/D |
(10,800) |
294,316 |
|
35% |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-07-01 |
4 |
AS |
$30.63 |
$309,701 |
D/D |
(10,000) |
260,293 |
|
35% |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-07-01 |
4 |
OE |
$0.16 |
$1,600 |
D/D |
10,000 |
270,293 |
|
- |
|
Turtle Cameron |
See Remarks |
|
2020-06-30 |
4 |
S |
$32.65 |
$326,623 |
D/D |
(10,000) |
9,823 |
|
-23% |
|
Turtle Cameron |
See Remarks |
|
2020-06-30 |
4 |
OE |
$0.16 |
$2,320 |
D/D |
10,000 |
19,823 |
|
- |
|
Lo Andrew |
Director |
|
2020-06-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
205,583 |
|
22% |
|
Lo Andrew |
Director |
|
2020-06-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
40,599 |
|
22% |
|
Scott Randal W |
Director |
|
2020-06-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,000 |
|
22% |
|
Kumar Neil |
CEO and President |
|
2020-06-08 |
4 |
AS |
$30.01 |
$318,125 |
I/I |
(10,600) |
2,308,842 |
|
32% |
|
Stephenson Brian C |
See Remarks |
|
2020-06-08 |
4 |
AS |
$30.00 |
$60,002 |
D/D |
(2,000) |
305,116 |
|
32% |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-06-08 |
4 |
AS |
$30.00 |
$18,185 |
D/D |
(606) |
260,293 |
|
32% |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-06-03 |
4 |
AS |
$30.04 |
$23,549 |
D/D |
(784) |
261,399 |
|
33% |
|
Stephenson Brian C |
See Remarks |
|
2020-06-03 |
4 |
AS |
$30.04 |
$48,072 |
D/D |
(1,600) |
307,116 |
|
33% |
|
Kumar Neil |
CEO and President |
|
2020-06-03 |
4 |
AS |
$30.05 |
$178,173 |
I/I |
(5,930) |
2,319,442 |
|
33% |
|
Stephenson Brian C |
See Remarks |
|
2020-06-01 |
4 |
AS |
$29.31 |
$211,401 |
D/D |
(7,200) |
308,716 |
|
37% |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-06-01 |
4 |
AS |
$29.26 |
$75,912 |
D/D |
(2,585) |
261,683 |
|
37% |
|
Kumar Neil |
CEO and President |
|
2020-06-01 |
4 |
AS |
$29.13 |
$2,335,390 |
I/I |
(80,000) |
2,325,372 |
|
37% |
|
Roberts George R |
|
|
2020-05-28 |
4 |
S |
$33.39 |
$79,791,749 |
I/I |
(2,389,690) |
34,510,971 |
|
-10% |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-05-26 |
4 |
OE |
$1.05 |
$19,283 |
D/D |
18,365 |
264,268 |
|
- |
|
Sinha Uma |
Chief Scientific Officer |
|
2020-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
1,523 |
15,523 |
|
- |
|
Henderson Michael Thomas |
Chief Business Officer |
|
2020-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
83,541 |
245,903 |
|
- |
|
Mccormick Frank |
Chairman of Oncology |
|
2020-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
39,042 |
1,300,568 |
|
- |
|
Stephenson Brian C |
See Remarks |
|
2020-05-05 |
4 |
AS |
$30.49 |
$173,959 |
D/D |
(5,706) |
315,916 |
|
23% |
|
288 Records found
|
|
Page 9 of 12 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|